HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Graduate School of Dental Medicine / Faculty of Dental Medicine >
Peer-reviewed Journal Articles, etc >

Biglycan, tumor endothelial cell secreting proteoglycan, as possible biomarker for lung cancer

This item is licensed under: Creative Commons Attribution 4.0 International

Files in This Item:

The file(s) associated with this item can be obtained from the following URL:https://doi.org/10.1111/1759-7714.13907


Title: Biglycan, tumor endothelial cell secreting proteoglycan, as possible biomarker for lung cancer
Authors: Hirofumi, Morimoto Browse this author
Yasuhiro, Hida Browse this author →KAKEN DB
Nako, Maishi Browse this author →KAKEN DB
Nishihara, Hiroshi Browse this author →KAKEN DB
Hatanaka, Yutaka Browse this author →KAKEN DB
Li, Cong Browse this author
Matsuno, Yoshihiro Browse this author →KAKEN DB
Nakamura, Toru Browse this author →KAKEN DB
Hirano, Satoshi Browse this author →KAKEN DB
Hida, Kyoko Browse this author →KAKEN DB
Keywords: angiogenesis
biglycan
endothelial cell
lung cancer
tumor progression
Issue Date: 11-Mar-2021
Publisher: John Wiley & Sons
Journal Title: Thoracic Cancer
Volume: 12
Issue: 9
Start Page: 1347
End Page: 1357
Publisher DOI: 10.1111/1759-7714.13907
PMID: 33709550
Abstract: Objectives In lung cancer, surgery remains the most curative treatment and limited resection is beneficial for patients with low cardiopulmonary function and low malignancy tumors. However, there are no biomarkers of low malignancy to select candidates for limited resection without compromising the outcome of treatments. Recently we identified biglycan (BGN) as a tumor endothelial cell (TEC) marker that is associated with tumor progression in various cancers. In this study, we analyzed the association between BGN expression in TECs in lung cancer and cancer progression in patients. Materials and Methods First, we performed immunohistochemistry of BGN with resected lung tumor tissues of 155 patients who had undergone thoracic surgery and analyzed the correlation between BGN-positive vessel density in primary lung tumors and clinicopathological factors. Second, we measured the BGN levels in preoperative serum of other 46 patients with lung cancer by ELISA, and analyzed the correlation between BGN expression in tumor tissues and blood BGN levels. Results High BGN expression in the TECs was significantly associated with T factor, and was a significant negative predictor. BGN levels in preoperative serum of 46 patients with lung cancer was significantly correlated with BGN expression in the TECs. Preoperative serum BGN level was significantly lower in healthy volunteers and less invasive adenocarcinoma than in invasive adenocarcinoma and other lung carcinomas. These results suggest that low BGN level in preoperative serum in patients with lung cancer might indicate low malignancy. Conclusions BGN can be a potential biomarker for lung cancer.
Rights: https://creativecommons.org/licenses/by/4.0/
Type: article
URI: http://hdl.handle.net/2115/81151
Appears in Collections:歯学院・歯学研究院 (Graduate School of Dental Medicine / Faculty of Dental Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Export metadata:

OAI-PMH ( junii2 , jpcoar_1.0 )

MathJax is now OFF:


 

 - Hokkaido University